- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT06615739
Acessório abrangente de tecido SRS Regenerex
Estudo de acompanhamento clínico pós-comercialização para fornecer dados de segurança, desempenho e benefícios clínicos do sistema de revisão segmentar abrangente (SRS) Regenerex Tissue Attachment Augments - um estudo retrospectivo de inscrição e acompanhamento prospectivo de série consecutiva
The objective of this retrospective and prospective consecutive series data collection is to confirm safety, performance, and clinical benefits of the Comprehensive SRS Regenerex Tissue Attachment Augments when used for limb salvage arthroplasty.
Visão geral do estudo
Status
Intervenção / Tratamento
Descrição detalhada
Consecutive subjects implanted with Comprehensive SRS Regenerex Tissue Attachment Augments according to the approved indications, with the longest-term follow-up possible, will be identified and invited to participate in the study.
The primary objective is the assessment of safety by analyzing implant survivorship. This will be established by recording the incidence and frequency of revisions, complications, and adverse events. Relation of the events to the implant and/or procedure should be specified.
The study will include one site. There will be a maximum of 103 patients enrolled in the study.
Tipo de estudo
Inscrição (Real)
Contactos e Locais
Locais de estudo
-
-
Florida
-
Boca Raton, Florida, Estados Unidos, 33432
- Toman Orthopedics and Sports Med
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Método de amostragem
População do estudo
Subjects must meet the inclusion criteria to be enrolled into the study. Subjects who meet any of the exclusion criteria should not be enrolled into the study.
The study population will comprise a consecutive cohort of up to 103 subjects implanted using the Comprehensive SRS Regenerex Tissue Attachment Augments.
Descrição
Inclusion Criteria:
-
Patient must be 18 years of age or older.
-
Patient must be willing and able to follow directions.
-
The Comprehensive Segmental Revision System was used in cases of:
- Non-inflammatory degenerative joint disease including osteoarthritis and avascular necrosis.
- Revision where other devices or treatments have failed.
- Correction of functional deformity.
- Oncology applications including bone loss due to tumor resection.
-
Proximal or total humeral replacement, for: Treatment of acute or chronic fractures with humeral head (shoulder) involvement, which are unmanageable using other treatment methods.
-
Distal or total humeral replacement for: Treatment of acute or chronic fractures with humeral epicondyle (elbow) involvement, which are unmanageable using other treatment methods.
-
Biomet Comprehensive Segmental Revision System was used in a reverse application in patients whose shoulder joint has a grossly deficient rotator cuff with severe arthropathy and/or previously failed shoulder joint replacement with a grossly deficient rotator cuff for proximal humeral replacement. The patient must be anatomically and structurally suited to receive the implants and a functional deltoid muscle is necessary.
-
The Comprehensive Segmental Revision System was used with bone cement in distal humeral and total humeral applications.
-
Regenerex Tissue Attachment Augments were used in combination with the Comprehensive Segmental Revision System
Exclusion Criteria:
-
Absolute contraindications:
- Infection
- Sepsis
- Osteomyelitis
- Patient is a prisoner
- Patient is a current alcohol or drug abuser
- Patient has a psychiatric illness or cognitive deficit that will not allow for proper informed consent
- Patient is unwilling to consent
-
Relative contraindications:
- Uncooperative patient or patient with neurologic disorders who is incapable of following directions
- Osteoporosis
- Metabolic disorders which may impair bone formation
- Osteomalacia
- Distant foci of infections which may spread to the implant site
- Vascular insufficiency, muscular atrophy, or neuromuscular disease
-
The Comprehensive Segmental Revision System was used in a reverse shoulder application in patients receiving radiation therapy
-
The Comprehensive Segmental Revision System was used without bone cement in distal humeral and total humeral applications.
-
Regenerex Tissue Attachment Augments weren't used during the patient's surgery
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Modelos de observação: COHORT
- Perspectivas de Tempo: OTHER
Coortes e Intervenções
Grupo / Coorte |
Intervenção / Tratamento |
|---|---|
|
Comprehensive Regenerex Tissue Attachment Augments
Regenerex Tissue Attachment Augments were used in combination with the Comprehensive Segmental Revision system |
Patient will have been previously implanted with Regenerex Tissue Attachment Augments in combination with the Comprehensive Segmental Revision System |
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Kaplan Meier Implant Survivorship
Prazo: Up to 10 Years
|
This will be established by recording the incidence and frequency of device revisions. Kaplan-Meier survival analysis is a statistical method that estimates survival rates over time and accounts for factors that can affect implant survival. |
Up to 10 Years
|
|
Safety Assessement
Prazo: Up to 10 Years
|
This will be established by recording the incidence and frequency of complications and adverse events. Relation of the events to the implant and/or procedure will be specified. |
Up to 10 Years
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Assessment of performance and clinical benefits by recording patient reported QuickDASH
Prazo: Up to 10 Years
|
QuickDASH, or Quick Disabilities of the Arm, Shoulder, and Hand, is a questionnaire that measures the impact of upper limb musculoskeletal disorders on physical function and symptoms. The QuickDASH has 11 items that cover six domains: Daily activities: How much difficulty the patient has performing physical activities Symptoms: How severe the patient's pain and tingling is Social function: How the patient's problem affects their social activities Work function: How the patient's problem affects their work Sleep: How the patient's problem affects their sleep Confidence: How the patient's problem affects their confidence Each item is rated on a 5-point Likert scale, with 1 being no difficulty and 5 being unable. The score is then converted to a 100-point scale, with 100 representing the greatest disability. |
Up to 10 Years
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Diretor de estudo: Erin Osborn, Zimmer Biomet
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Conclusão Primária (Real)
Conclusão do estudo (Real)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Outros números de identificação do estudo
- CMU2024-12E
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Descrição do plano IPD
IPD may not be shared due to this being a single center retrospective enrollment/prospective FUP with one single reference point. Additionally, data is being collected for EU regulatory purposes.
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
produto fabricado e exportado dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .